向KAT7可以抑制结直肠癌的进展
Hao Wang1,2, Tianwang Guan3,4,5, Rong Hu1,2
1Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Theranostics
|January 16, 2025
概括
高KAT7表达通过激活MAPK/ERK通路驱动结直肠癌 (CRC) 的进展. 向KAT7为预后不佳的CRC患者提供了一个有前途的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 结肠直肠癌 (CRC) 仍然是癌症死亡的一个重要原因.
- 表观遗传变化与CRC的发展和进展有关.
- 在CRC中,KAT7的特定作用,基酸转移酶,尚不清楚.
研究的目的:
- 研究KAT7在结直肠癌中的表达和预后意义.
- 阐明KAT7在CRC细胞行为和瘤发生中的功能作用.
- 揭示KAT7对CRC进展的贡献背后的分子机制.
主要方法:
- 在CRC患者数据 (GEO数据库) 中分析KAT7表达.
- 在体外测试 (细胞活力,殖民地形成,流细胞计,迁移,入侵) 和体内研究 (小鼠模型).
- 分子分析包括西部斑,免疫组织化学,RNA测序和ChIP-qPCR.
主要成果:
- KAT7在CRC上升调节,并与患者的生存率差相关.
- KAT7的淘汰抑制了CRC细胞的增殖,迁移,入侵和转移,而过度表达增强了这些过程.
- KAT7通过H3K14乙化促进MRAS转录,激活MAPK/ERK通路并驱动CRC瘤发生.
结论:
- KAT7是结直肠癌进展和转移的关键驱动因素.
- 在CRC中,KAT7的酶活性对其致癌功能至关重要.
- KAT7是改善结直肠癌患者治疗结果的潜在治疗标.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


